Drug Type Therapeutic vaccine, mRNA vaccine |
Synonyms KRAS Neoantigen mRNA Vaccine(Suzhou Abogen Biosciences), ABO 2102, ABO2102 |
Target |
Action inhibitors |
Mechanism KRAS inhibitors(GTPase KRas inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | China | 24 Sep 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 24 Sep 2024 | |
KRAS G12D mutation Solid Tumors | Phase 1 | China | 24 Sep 2024 | |
KRAS G12D mutation Solid Tumors | Phase 1 | China | 24 Sep 2024 | |
KRAS Mutant Pancreatic Cancer | Phase 1 | China | 24 Sep 2024 | |
KRAS Mutant Pancreatic Cancer | Phase 1 | China | 24 Sep 2024 | |
Non-Small Cell Lung Cancer | Phase 1 | China | 24 Sep 2024 | |
Non-Small Cell Lung Cancer | Phase 1 | China | 24 Sep 2024 | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | China | 24 Sep 2024 | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | China | 24 Sep 2024 |